Form D · Biotechnology
Eli Science Inc.
Montreal, A8 · CIK 0002080801
Offering snapshot reported Aug 22, 2025 · SEC filing
- Reported sold
- $1.06M Indefinite offering
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jan 31, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 22, 2025 | Initial | $1,064,967 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-555611
Source: Form D, filed Aug 22, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Cortina | Director, Executive |
| Assia Grazioli Venier | Director |
| Mona Minhas | Director |
| Marina Pavlovic Rivas | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1001 Rue Lenoir Suite B520
Montreal, A8, H4C2Z6
Montreal, A8, H4C2Z6